{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.95","estimateComment":"Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia vs. Non-Asia) and tumor staging (II vs. III vs. IVa)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00589","pValueComment":"One-sided p-value based on log-rank test stratified by geographic region (Asia vs. Non-Asia) and tumor staging (II vs. III vs. IVa)","paramType":"Hazard Ratio (HR)","paramValue":"0.80","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event","groupId":"OG000","lowerLimit":"36.2","upperLimit":"NA","value":"47.0"},{"groupId":"OG001","lowerLimit":"22.1","upperLimit":"34.7","value":"26.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"502"},{"groupId":"OG001","value":"505"}],"units":"Participants"}],"description":"EFS was based on RECIST 1.1 as assessed by the investigator and was defined as the time from randomization to the first of the following events: radiographic disease progression per RECIST 1.1; local or distant recurrence as assessed by CT scan or biopsy if indicated (for participants who were disease free after surgery); clinical progression as evidenced by peritoneal carcinomatosis confirmed by preoperative laparoscopy or laparotomy (for participants who were confirmed to be free of peritoneal involvement by laparoscopy at screening); or death due to any cause. A second primary malignancy, or radiographic progressive disease (PD) during the neoadjuvant phase that does not preclude successful surgery (i.e., disease free after surgery), were not considered EFS events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant and adjuvant pembrolizumab + XP/FP and neoadjuvant and adjuvant pembrolizumab + FLOT Cohort treatment arms combined","id":"OG000","title":"Pembrolizumab + XP/FP and Pembrolizumab + FLOT Cohort Combined"},{"description":"Neoadjuvant and adjuvant placebo+XP/FP and neoadjuvant and adjuvant placebo+FLOT Cohort treatment arms combined","id":"OG001","title":"Placebo + XP/FP and Placebo + FLOT Cohort Combined"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all randomized participants in the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, as pre-specified per protocol.","reportingStatus":"POSTED","timeFrame":"Up to approximately 75 months","title":"Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts","type":"SECONDARY","unitOfMeasure":"Months"}